Trials / Withdrawn
WithdrawnNCT01449357
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients With Non-Small Cell Lung Cancer Who Have Progressive Disease After Treatment With Tyrosine Kinase Inhibitors
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Genmab · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | zalutumumab | IV infusion, 16mg/kg on weekly basis until DP |
Timeline
- First posted
- 2011-10-10
- Last updated
- 2011-10-10
Source: ClinicalTrials.gov record NCT01449357. Inclusion in this directory is not an endorsement.